Abstract: In gene expression frequency analysis, a vector primer to which each cDNA is ligated is formed by synthesizing the cDNA from each mRNA using by a vector primer having a poly(T) sequence; each cDNA sequence is converted to a tag on the vector primer; a concatemer is formed by ligating the obtained tags via a sequence that enables recognition of ends of the tags; and the nucleotide sequence of the concatemer is analyzed.
Abstract: Methods and compounds are provided for detecting target molecules in a sample using specific binding assays. In particular, methods are provided for detecting a nucleic acid target in a sample. In one embodiment, the method comprises hybridizing a nucleic acid target, comprising a target nucleic acid sequence, to a nucleic acid probe, comprising a probe nucleic acid sequence, wherein the target comprises a binding ligand. The hydridized target is contacted with a receptor comprising multiple sites capable of binding the binding ligand to complex the receptor to the binding ligand, and the receptor is contacted with an amplification reagent, comprising a plurality of the binding ligands, to complex the amplification reagent to the receptor. The presence of the complexed amplification reagent then is detected, for example, by detecting the presence of a detectable label, such as a fluorescent label, for example, on the receptor or the amplification reagent.
Type:
Grant
Filed:
February 6, 2001
Date of Patent:
October 19, 2004
Assignee:
Affymetrix, Inc.
Inventors:
Martin J. Goldberg, Govinda Rao S. Yelagalawadi, Eugene Yuji Tanimoto, Huu Minh Tran, Helin Dong, David Lockhart, Thomas B. Ryder, Janet A. Warrington, Jody Beecher
Abstract: The present invention relates to polynucleotides associated with angiogenesis-related disorders. The present invention also relates to canine endostatin genes, novel genes associated with angiogenesis-related disorders, such as cancer. The invention encompasses endostatin nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof, endostatin gene products and antibodies directed against such gene products, cloning vectors containing mammalian endostatin gene molecules, and hosts that have been genetically engineered to express such molecules. The invention further relates to methods for the identification of compounds that modulate the expression of endostatin genes and gene products and to using such compounds as therapeutic agents in the treatment of angiogenesis-related disorders, e.g., cancer. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of angiogenesis-related disorders, e.g.
Abstract: The present invention relates to a method for the rapid and reliable detection of drug-selected mutations in the HIV protease gene allowing the simultaneous charaterization of a range of codons involved in drug resistance using specific sets of probes optimized to function together in a reverse-hybridization assay.
Abstract: Genetic markers in the Porcine melanocortin-4 receptor (MC4R) gene are disclosed which are associated with fat content, growth rate, and feed consumption. Further, novel sequence data from regions of the gene are disclosed which may be used in a PCR test to screen for the presence of the marker. The genetic marker may be used to screen animals for breeding purposes which have the desired traits regarding fat content, growth rate, and feed consumption. Kits which take advantage of the PCR test are also disclosed.
Type:
Grant
Filed:
July 24, 2000
Date of Patent:
October 12, 2004
Assignee:
Iowa State University Research Foundation, Inc.
Inventors:
Max F. Rothschild, Kwan Suk Kim, Niels J. Larson
Abstract: Fluid compositions and methods for lubrication of mammalian joints are disclosed, including both natural and artificial fluids. Synovial fluid acts to lubricate the bearing surfaces of bones and bone-like structures which are held in frictional contact within biological joints. Such fluids may be used to treat arthritic, injured, and diseased joints. Synovial fluid containing a dextran-based hydrogel with lipids provides enhanced rheological and tribological properties of such a fluid. Phospholipids are particularly useful in dextran-based compositions for synovial fluid. One phospholipid that can be used advantageously in synovial fluid is dipalmitoyl phosphatidylcholine (DPPC).
Type:
Grant
Filed:
May 11, 2000
Date of Patent:
October 5, 2004
Assignee:
Clemson University
Inventors:
Julie-Anne Mason Burdick, Martine Laberge, Gary Lickfield
Abstract: Arrays of polypeptides are generated by translation of nucleic acid sequences encoding the polypeptides at a plurality of addresses on the array.
Type:
Grant
Filed:
January 22, 2002
Date of Patent:
October 5, 2004
Assignee:
President and Fellows of Harvard College
Abstract: The invention relates to methods of detecting a drug resistant HIV in a subject. The methods include detecting mutations associated with drug resistance in an HIV 2-LTR circle DNA molecule obtained from a cell of an HIV-positive subject, e.g, an HIV-1-positive human.
Abstract: The invention features methods and reagents useful for the treatment of excessive or insufficient apoptosis in cells, and, particularly, in germ-line cells. The invention is useful in treating testicular cancers, cancers of germ-line cells, cancers in non-germ-line cell tissues, infertility (e.g., male infertility), and for birth control (e.g., male birth control).
Abstract: A pharmaceutical composition is disclosed, as well as its use in tumour diagnosis, therapy and prevention, methods for diagnosing, treating and preventing tumours, and antibodies and their use.
Abstract: A method is provided for determining the susceptibility of a NIDDM patient towards sulfonylurea therapy by obtaining a sample from a NIDDM patient where the sample includes nucleic acid molecules containing a fragment of the SUR1 gene comprising the nucleotide in position −3 of exon 16 and detecting the presence or absence of the −3 t allele in position −3 of exon 6 whereby the presence of at least one −3 t allele identifies a NIDDM patient with a high susceptibility towards sulfonylurea therapy.
Type:
Grant
Filed:
October 19, 2001
Date of Patent:
September 14, 2004
Assignees:
Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale
(Inserm)
Inventors:
Philippe Amouyel, Nicole Helbecque, Aline Meirhaeghe
Abstract: The invention concerns a method for selecting tumours expressing HLA-G, sensitive to an anticancer treatment, which inhibits or prevents the HLA-G activity of said tumours and the uses thereof. Said method enable to establish either the HLA-G, transcription profile of a solid tumour or the HLA-G expression profile of a solid tumour. The method for establishing the HLA-G transcription profile consists in: (i) drawing a tumoral sample; (ii) extracting the mRNA; (iii) reverse transcription (RT) of said RNA: (iv) successive or simultaneous amplification of the cDNA's obtained in (iii) in the presence of primers specific to each HLA-G isoform and analysing the resulting amplification products, by electrophoresis and/or specific hybridisation and (v) establishing said sample HLA-G transcription profile.
Type:
Grant
Filed:
October 13, 2000
Date of Patent:
September 14, 2004
Assignee:
Commissariat a l'Energie Atomique
Inventors:
Edgardo Delfino Carosella, Jean Dausset, Philippe Moreau, Pascale Paul, Nathalie Rouas-Freiss
Abstract: This invention provides the identification of a truncation polymorphism of the mdr1 gene that is linked to ivermectin sensitivity in subjects, such as collies. Also provided are methods for detecting drug transport sensitivity in a subject, and animal models and in vitro cell systems using cells from animals having an mdr1 truncation.
Type:
Grant
Filed:
January 10, 2002
Date of Patent:
September 14, 2004
Assignee:
Washington State University Research Foundation
Abstract: The present invention is broadly directed to therapeutic molecules capable of inter alia modulating apoptosis in mammalian cells. The therapeutic molecules of the present invention encompass genetic sequences and chemical entities capable of regulating expression of a novel mammalian gene belonging to the bcl-2 family and which promotes cell survival. The therapeutic molecules of the present invention may have further utility in delaying cell cycle entry. In addition, the present invention extends to chemical entities capable of modulating activity and function of the translation product of said novel gene of the bcl-2 family. The present invention also extends to the translation product of the novel gene of the bcl-2 family and its use in, for example, therapy, diagnosis, antibody generation and as a screening tool for therapeutic molecules capable of modulating physiological cell death or survival and/or modulating cell cycle entry.
Type:
Grant
Filed:
March 29, 1999
Date of Patent:
September 14, 2004
Assignee:
Cerylid Pty., Ltd.
Inventors:
Suzanne Cory, Jerry McKee Adams, Leonie M. Gibson, Shaun P. Holmgreen
Abstract: The invention relates to methods for cloning DNA molecules using recE/recT-mediated homologous recombination mechanism between at least two DNA molecules where one DNA molecule is a circular or linear DNA molecule and the second DNA molecule is a circular DNA molecule, and the second DNA molecule contains two regions with sequence homology to the first DNA molecule. Competent cells and vectors are also described.
Abstract: The invention provides isolated nucleic acids and their encoded proteins that are involved in tocopherol or plastoquinone biosynthesis. The invention further provides recombinant expression cassettes, host cells, transgenic plants, and antibody compositions. The present invention provides methods and compositions relating to altering phytyl/prenyltransferase protein content and/or composition of plants.
Type:
Grant
Filed:
April 28, 2000
Date of Patent:
September 7, 2004
Assignees:
Pioneer Hi-Bred International, Inc., Board of Regents of the University and Community College
Systems of Nevada on Behalf of the University of Nevada,
Reno
Inventors:
Dean Della Penna, Eva Collakova, Sean J. Coughlan, Timothy G. Helentjaris
Abstract: A method of detecting an enzyme-mediated DNA cleavage reaction in a fluorometric assay is provided. The method can be used to detect DNA cleavage caused by restriction endonucleases, retroviral integrase enzymes, DNases, RNases, or enzymes utilized in other strand separating processes in molecular biology.
Type:
Grant
Filed:
April 30, 1998
Date of Patent:
September 7, 2004
Assignee:
Georgetown University
Inventors:
Myun Ki Han, S. Paul Lee, Jack Chirikjian
Abstract: Compositions and methods are provided for the modulation of ras expression. Oligonucleotides are provided which are targeted to nucleic acids encoding human ras. Oligonucleotides specifically hybridizable with mRNA encoding human H-ras, Ki-ras and N-ras are provided. Such oligonucleotides can be used for therapeutics and diagnostics as well as for research purposes. Methods are also disclosed for modulating ras gene expression in cells and tissues using the oligonucleotides provided, and for specific modulation of expression of activated ras. Methods for diagnosis, detection and treatment of conditions, or particular cancers, associated with ras are also disclosed.
Type:
Grant
Filed:
May 22, 2000
Date of Patent:
August 31, 2004
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
Brett P. Monia, Lex M. Cowsert, Muthiah Manoharan
Abstract: The present invention provides polynucleotides having base sequences of sequence Nos. 1 to 4, as polynucleotides having polymorphism sites capable of being useful indicators for prediction of validity of interferon therapy.
Type:
Grant
Filed:
March 22, 2001
Date of Patent:
August 31, 2004
Assignee:
Kabushiki Kaisha Toshiba
Inventors:
Minako Hijikata, Shunji Mishiro, Yasuhiko Oota, Koji Hashimoto